Cell-Free Protein Synthesis: The Next Generation of Biopharmaceutical Production

 

Modern medicine depends on biopharmaceutical products like insulin, vaccines, and monoclonal antibodies, but traditional cell-based production faces significant obstacles, particularly with "difficult-to-express" proteins that are toxic or prone to misfolding. A novel substitute is provided by Cell-Free Protein Synthesis (CFPS). CFPS removes host cell limitations by lysing cells and using only the active cytoplasmic machinery, including transcription and translation components, without the living cell membrane. This open-system platform is a highly effective, quickly scalable, and adaptable solution for contemporary biomanufacturing since it directs all available resources toward the expression of the target gene.

Schematic of Cell-free Protein synthesis

Depending on the complexity of the target molecule, CFPS uses extracts from both prokaryotic and eukaryotic hosts to accomplish this. Eukaryotic extracts, such as Chinese Hamster Ovary (CHO) or human cell lines, are preferred when precise post-translational modifications, like glycosylation, are needed, even though E. coli extracts are very economical and produce large amounts of protein. Recent developments demonstrate the extraordinary speed and yields that can be obtained with this platform. In contrast to the usual seven or more days needed for conventional cell-based transfection, monoclonal antibodies constructed using CHO extracts in a semi-continuous format reached yields over 100 mg/L in just two days. Furthermore, complex antibodies like IgG achieved yields up to 500 mg/L within 24 hours, while viral vaccines for Human Norovirus were synthesized in E. coli lysate in a mere four hours, reaching a 1 g/L yield and slashing projected costs down to an accessible five dollars per dose.

The cellular survival mechanisms that frequently restrict industrial yields in conventional systems are essentially bypassed by this platform. Researchers can directly observe reactions, modify DNA templates, and add artificial reagents or particular chaperones to maximise folding in an open, cell-free environment. Compared to live CHO cell cultures, where the dense intracellular cytoplasm frequently pushes misfolded proteins into inactive inclusion bodies, this is a significant improvement. Additionally, CFPS removes the metabolic strain brought on by overexpressing a single foreign product, which in live cells typically triggers inhibitory negative feedback pathways. Additionally, CFPS significantly lowers unwanted side reactions and increases diffusion rates because it is an open environment diluted up to twenty times more than a living cell. From a facility perspective, manufacturing can avoid costly Biosafety Level 2 containment infrastructure by not using live genetically modified organisms, which results in significant setup and maintenance savings. 

Before achieving widespread industrial dominance, CFPS must overcome a few technical obstacles despite its enormous potential. Current costs are increased by the supply chain's reliance on costly energy-donating molecules like ATP and GTP, which has prompted extensive research into less expensive alternative energy regeneration systems. Additionally, byproduct accumulation can cause conventional batch formats to have short reaction lifespans, which forces researchers to develop continuous-exchange cell-free or hollow-fiber bioreactor designs in order to prolong production times.

Future developments in CFPS will concentrate on on-demand, decentralised biomanufacturing. Lyophilization produces extremely stable, cell-free extracts that can be stored ambiently for an extended period of time. This eliminates cold-chain logistics and only requires aqueous reconstitution to reactivate the metabolic translation machinery. This makes it possible to synthesise patient-specific cancer vaccines and vital countermeasures in a matter of hours at distant or clinical locations using automated, microfluidic, or modular platform devices.

REFERENCES

Chiba, C.H., Knirsch, M.C., Azzoni, A.R., Moreira, A.R. and Stephano, M.A., 2021. Cell-free protein synthesis: advances on production process for biopharmaceuticals and immunobiological products. Biotechniques, 70(2), pp.126-133.

Jin, X. and Hong, S.H., 2018. Cell-free protein synthesis for producing ‘difficult-to-express’ proteins. Biochemical Engineering Journal, 138, pp.156-164.

Image sources: 

https://www.drugdiscoverynews.com/is-cell-free-protein-synthesis-the-key-to-drugging-the-undruggable-16451

https://www.genengnews.com/news/cell-free-protein-synthesis-made-flexible-and-accessible/